[UPDATE 8/20/17: Read the paper here.]Congratulations to lab alumnist Matthew on the acceptance of his manuscript acceptance by PLoS One. This study conducted at cc-TDI explored 2 potential drugs for rhabdomyosarcoma. One drug targeted EphB4, and the other drug targeted EphrinB2. Co-authors include cc-TDI lab member Megan, lab alumni Zia, Matthew Sv., and Michael. Collaborators included Atiya Mansoor (OHSU); Pali Kaur, Carol Bult, Sunny Xiang and Jim Keck (JAX); Martin Goros and Joel Michalek (UTHSCSA); and Valery Krasnoperov and Parkash Gill (Vasgene Therapeutics). This study was sponsored by the Thumbs Up for Lane Goodwin Foundation, Live Like Bella Foundation, and the Alex’s Lemonade Stand Foundation.